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Abstract. The year 2017 marks the 30th anniversary of the birth of modern deep brain stimulation (DBS), which was
introduced by Benabid, Pollak et al. in 1987, initially targeting the motor thalamus to treat tremor, and subsequently targeting
the subthalamic nucleus (STN) for treatment of symptoms of advanced Parkinson’s disease (PD). STN DBS is undoubtedly
“the most important discovery since levodopa”, as stated by David Marsden in 1994. In 2014, The Lasker–DeBakey Clinical
Medical Research Award to “honor two scientists who developed deep brain stimulation of the subthalamic nucleus”, was
bestowed upon Benabid and DeLong. STN DBS remains today the main surgical procedure for PD, due to its effectiveness in
ameliorating PD symptoms and because it is the only surgical procedure for PD that allows a radical decrease in medication.
Future improvements of DBS include the possibility to deliver a “closed-loop”, “on demand” stimulation, as highly preliminary
studies suggest that it may improve both axial and appendicular symptoms and reduce side effects such as dysarthria. Even
though DBS of the subthalamic nucleus is the main surgical procedure used today for patients with PD, all patients are not
suitable for STN DBS; as a functional neurosurgeon performing since more than 25 years various surgical procedures the
aim of which is not to save life but to improve the patient’s quality of life, I consider that the surgery should be tailored to
the patient’s individual symptoms and needs, and that its safety is paramount.
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“I used to wonder years ago when the anxiety,
tension, and pain of the decision . . . would dis-
appear. I now know the answer to that question.
When? Never – that’s when.”
Irving S. Cooper: The Vital Probe. My life as a
brain surgeon (1981).
INTRODUCTION
My mentor Lauri Laitinen (1928–2005), – the neu-
rosurgeon from Umea˚, Sweden, who pioneered the
renaissance of surgery for Parkinson’s disease (PD) in
the mid 1980s by resurrecting Leksell’s posteroven-
tral pallidotomy [1] – wrote in 2003, in his last
publication pertinent to PD:
“In my opinion, DBS of the subthalamic nucleus
represents a most important step of the last decade
in the surgical treatment of Parkinson’s disease. We
owe a great debt to Professor Alim-Louis Benabid
for his intelligence and courage to have begun the
implantation of chronic electrodes in the STN” [2].
It was the discovery of Bergman, Wichman and
DeLong in 1990 [3] that lesions of the subthalamic
nucleus (STN) alleviated experimental parkinsonism
in the MPTP monkey model of PD, that paved the
way to target that nucleus with high frequency Deep
Brain stimulation (DBS) in humans.
The first paper about DBS of the STN (unilat-
eral surgery in one patient) was published in French
in 1993 [4] and the second paper describing three
patients bilaterally operated was published in the
Lancet in 1995 [5]. However, already in March 1994,
at the 11th Parkinson’s Disease symposium in Rome,
Grenoble neurologist Pierre Pollak presented the
results of DBS of the STN, including a video of the
first patients. The late Professor David Marsden, who
was present in the audience, publicly stated then that
this was “the most important discovery since lev-
odopa” [6]. The honeymoon had begun, and in some
respect, it is still lasting. Here I retrace my 25 years of
clinical and academic activity in DBS for PD, high-
lighting its advantages and its shortfalls, as well as
providing a critical appraisal of the pertinent literature
on the subject of surgery for PD.
THE EARLY EUPHORIA
2017 marks the 30th birthday anniversary of mod-
ern DBS. It was in 1987 that Benabid, Pollak et al.
from Grenoble published their seminal paper on tha-
lamic DBS for tremor [7]. This procedure did not
make a dent in the field at that time because it was only
directed at the ventral intermediate nucleus (VIM)
of the thalamus for treatment of tremor. By con-
trast, the revival of posteroventral pallidotomy, that
happened at roughly the same period, addressed the
whole triad of cardinal PD symptoms (bradykinesia,
rigidity and tremor) as well as L dopa-induced dyski-
nesias. Hence, Laitinen’s posteroventral pallidotomy
was the main surgical procedure performed and pub-
lished worldwide in the 1990s [8]. Towards the turn
of the millennium STN DBS had gained momentum,
and because it could be done bilaterally in one ses-
sion and was efficient for bradykinesia, rigidity and
tremor, and allowed a radical decrease of medica-
tions, it almost completely superseded pallidotomy.
Initially, there were some reports that STN DBS could
even be neuroprotective, but this has unfortunately
not been confirmed [9].
Beginning in the early 1990s, I started to perform
DBS and gradually shifted from performing mainly
ablative surgery (pallidotomy, thalamotomy) towards
performing mainly DBS, first Vim DBS for tremor
and eventually pallidal and STN DBS for advanced
PD. This shift was driven by the widely held view
that DBS was non-destructive, adaptable, safe and
reversible, and could be done bilaterally in same sur-
gical session [10] (which was not possible in ablative
surgery). By the year 2000, some 50–60 patients
had had thalamic DBS at Umea˚ University Hospital,
where I was based, and about 12 patients had received
pallidal or STN DBS. In 1999, I published one of the
first reports describing the development of tolerance
to VIM thalamic DBS for tremor and the appearance
of severe rebound upon stopping stimulation [11].
In 2000, I published an illustrative case report about
one of the first patients of the STN DBS series, who
had preoperatively some cognitive decline and speech
problems, and in whom there was obvious discrep-
ancy between a striking amelioration of Parkinsonian
symptoms and a negative effect on the quality of life
due to two side effects of STN DBS: dysarthropho-
nia and increasing dementia [12]. This was one of the
first published reports drawing attention to the risks
of bilateral STN DBS on cognition and speech in
patients who present preoperatively with symptoms
in these domains.
The real and universal breakthrough of DBS in
STN and in DBS in the globus pallidus internus (GPi)
took place following the publication of the world-
wide multicenter trial in the New England Journal
of Medicine in September 2001, which remains one
of the most quoted in the field of DBS [13]. This
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was the paper on the basis on which DBS in STN
and GPi was approved by the United States Food and
Drug Administration. Something that was eyebrow-
raising in that paper, was that in Table 5, describing
adverse events, the authors mentioned only one sin-
gle stimulation-induced dysarthria in the 102 bilateral
STN DBS patients and zero dysarthria in the 41 bilat-
eral GPi DBS patients. This startlingly low level of
side effects enticed me to write a Letter to the Editor
pointing out this lapsus and I concluded my letter stat-
ing that “Deep-brain stimulation of the basal ganglia
is an efficient treatment for Parkinson’s disease, but
this method may lose credibility if its side effects are
not properly accounted for” [14]. Today, it is undis-
puted that dysarthria is one of the main side effects
of bilateral DBS in the STN, varying between zero
and 97% depending on how evaluation is done, when
after surgery and depending of course on electrode
location in the target area, among other variables
[15–18].
STN DBS: SELECTION CRITERIA
In the process of elucidating the best selection
criteria for patients for STN DBS, several studies
correlated the improvement following surgery to var-
ious patient-specific factors. The most notable were
papers by Charles et al. from Grenoble [19] and Wel-
ter et al. from Salpeˆtrie`re in Paris [20] confirming that
a good preoperative response to L-dopa, a shorter dis-
ease duration, a good cognitive status and a younger
age of patients were highly predictive of a good
response to STN DBS. Subsequently, reports started
to appear about behavioural side effects of DBS such
as apathy, depression, mania, marital conflicts, cog-
nitive decline, behavioural changes, etc [21–26], all
of which did put further constraints on which patients
would be considered eligible for this highly efficient
procedure. Despite the stringent selection criteria,
several centres only perform STN DBS and do not
offer any other surgery if patients do not fulfil criteria
for STN DBS. The concept of a surgical procedure
tailored to the status and symptoms of the patient,
that I introduced in 2000 [27] fell for many years
on deaf ears before eventually being recognized and
proposed by some authors [15, 28–30], and before
the Task Force of the International Movement Dis-
orders Society updated its recommendations in 2013
declaring that both STN DBS, GPi DBS and pallido-
tomy were evidence-based and approved for surgical
treatment of PD [31].
Be it as it may, STN DBS remains today the main
surgical procedure for PD, mainly, but not solely,
due to its effectiveness in ameliorating PD symp-
toms and because it is the only surgical procedure for
PD that allows a radical decrease in medication even
in patients with advanced PD. The well publicized
neurological, behavioural, and other side-effects of
STN DBS, such as obsessive compulsive disorders,
have in fact contributed to better understanding of the
pathophysiology and connectivities of the STN and
its surrounding area, and has drawn researchers from
allied areas such as psychiatry and behaviour to study
the role of DBS in these conditions [32].
MICROELECTRODE RECORDING OR
NOT?
In a paper from Toulouse published in 2007, the
authors evaluated the outcome of microelectrode-
guided STN DBS in relation to age of the patients
[33]: out of 45 consecutive patients aged 40–73 years,
four patients had symptomatic cerebral bleeding of
whom two patients, 71 and 69 years old, “experi-
enced cerebral bleeding and died”. Despite this (in
my opinion unacceptable) 4.5% surgical mortality,
the authors did not deal with what went wrong at
surgery. The issue of surgical morbidity and mor-
tality is ever present in the discussion on surgical
technique. I have never endorsed the technique of
microelectrode recording (MER) in DBS other than
as a scientific tool to be used in a research set-
ting on a limited number of patients, with their
informed consent, in order to answer specific sci-
entific questions [34]. This is because the available
literature demonstrates that repeated penetrations of
sharp microelectrodes along several tracks in the
brain do indeed increase the surgical risks including
haemorrhage, death, pneumocephalus, infections, as
well as increasing surgical time and costs [34–38],
without providing a measurable better outcome in
terms of improved UPDRS scores compared to tech-
niques that do not use MER. A meta-analysis by
Zrinzo et al. of all DBS publications with more than
40 patients has shown that MER results in far more
haemorrhage than image-guided DBS [38]. Indeed,
some of those who were most enthusiastic about
MER DBS have now abandoned this technique in
favour of image-guided DBS performed in patients
either awake or under general anaesthesia [39, 40].
The technique of stereotactic MRI-guided and stereo-
tactic MRI-verified DBS that relies on individual
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imaging of the brain target, and individual imaging
of the electrode in situ postoperatively, that I devel-
oped in Sweden in the early 1990s, and introduced
to Queen Square 15 years ago [41–44], has resulted
in zero surgical mortality in well over 1000 operated
patients.
THE “EARLYSTIM” TRIALS
The “logical” conclusion that some have drawn
from the fact that younger patients with short dis-
ease duration and good response to L-dopa would
constitute better candidates for STN DBS, was that
STN DBS should be performed at an earlier stage
of the disease. Instead of the typical 11–13 years
or more of disease duration before STN DBS [45,
46], Shu¨pbach et al. from Salpeˆtrie`re suggested per-
forming surgery after about 7 years of disease, just
when complications start to appear. In a report from
2007 [47], they followed 10 patients operated on
“early” for 18 months and compared their outcome
with 10 patients on best medical treatment. Only the
operated patients exhibited improvement in UPDRS
motor scores, in dyskinesia scores and in quality of
life (QoL), and were able to decrease their daily
doses of dopaminergic drugs by 57%. This led to the
famous German-French “Earlystim” multicenter in
2013, with 2-year follow up showing better QoL in
STN DBS patients than in matched patients receiv-
ing best medical treatment [48]. This study generated
controversy with editorials and commentaries. The
Editor of Lancet Neurology asked me to provide an
editorial comment, in which I wrote: “There is no
doubt that in the short to medium term, patients with
Parkinson’s disease who receive surgery will gen-
erally experience less severe symptoms than those
who remain only on best medical treatment, regard-
less of disease stage at baseline and even regardless
of what kind of surgery they receive (DBS or palli-
dotomy)” [49]. Given the heterogeneity of PD and
also heterogeneity of long term benefit from STN
DBS, I also wrote that “We do not know in the long
term who will continue to do well and who will
exhibit the issues well known to affect patients on
long-term STN neurostimulation, such as refractory
axial problems (speech, balance, and gait) and cogni-
tive problems.” [49]. I was comforted that my careful
attitude towards offering an invasive procedure such
as DBS before it is really warranted was supported
by neurologists who were the very pioneers of STN
DBS [50]
In any case, the “Earlystim” trial, that was suc-
cessful precisely because it was conducted in highly
selective and highly experienced centers, was used
widely in Medtronic’s adverts “Medtronic DBS
EARLYSTIM” blasting the message “Timing is
everything Why wait?”
Even more disturbing is the launch at Vanderbilt
University of a pilot trial for STN DBS even ear-
lier in the course of the disease [51]. The authors
included 30 patients, 15 to receive DBS and best
medical treatment, and 15 to continue on only best
medical treatment. Patient selection included a diag-
nosis of idiopathic PD with a duration of disease
of more than 6 months but less than 2 years, a
Hoehn & Yahr Stage of II when off medication,
and the patients should not exhibit fluctuations or
dyskinesias. Two of the DBS operated patients suf-
fered “serious adverse events” including one who was
left with a permanent deficit following basal ganglia
infarction [51]. Despite that, the authors concluded
that their study “met its primary endpoint related to
safety, demonstrating that chronic stimulation does
not produce greater declines in motor function com-
pared to the control group”. In a Letter to the Editor
[52] I wondered whether the rationale for this study
was to demonstrate that STN DBS does not make
people with PD worse? As a functional neurosur-
geon who dreads most of all a complication from
my surgery, a surgery-related basal ganglia infarc-
tion in one out of 15 operated patients who did
not even need surgery in the first place, is simply
unacceptable.
STN DBS OR GPI DBS?
Even though STN DBS has been, and still is, the
most published surgical procedure for PD, it has been
debated whether GPi DBS is equally effective [30,
53]. Proponents of GPi DBS, mostly in the US [15,
54–56], held the belief that it might be more lenient
than STN DBS in terms of behavioural side-effects,
while maintaining the same efficacy. Since efficacy
on motor symptoms has been the main driver for
the use of DBS, a multicenter study was designed
to test which of the two procedures, STN DBS or
GPi DBS, is most efficient for PD motor symp-
toms. This randomized trial [57] showed that both
procedures showed similar results at 2 years, with
25–28% improvement in the off-medication state,
rated on the motor part of UPDRS. This surprisingly
modest improvement is by any standard suboptimal,
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especially for STN DBS, compared to earlier work.
Incidentally, this reported 25–28% improvement was
in fact very similar to the extent of improvement in
randomized studies on unilateral pallidotomy, which
was the main surgical procedure for PD in the 1990s
[58–60].
GENDER DIFFERENCES IN SURGERY
FOR PD
Another issue that caught the attention of our team
was the gender distribution of PD patients undergo-
ing surgery. It started by the observation that among
all patients operated for PD at Umea˚ University Hos-
pital since the start of the Neurosurgery department in
1969, men were twice as many as women regardless
of surgical procedure (thalamotomy, pallidotomy or
DBS). This led to a comprehensive review of the inter-
national literature published between January 1985
and February 1999, focusing on gender distribution of
PD patients undergoing stereotactic surgery. Regard-
less of the geographical origin of the publication and
the surgical procedure, there were at least twice as
many men with PD who had surgery as women [61].
A subsequent further review of more recent literature
(2000–2009) limited to STN DBS showed similar
results [62].
THE LONG-TERM RESULTS OF DBS
Publications describing long term outcomes of
surgery for PD are scarce. In 2001, I published
the first report on very long term (10 year) results
of pallidotomy [63]. The main conclusion of that
paper was: “The long term effect of posteroven-
tral pallidotomy (PVP) on dyskinesias was not only
curative but also appeared to be prophylactic. Fur-
ther progression of axial and akinetic symptoms,
and an eventual decline in cognition together with
other concomitant illnesses, contributed to increased
disability in several patients.” [63]. Indeed sev-
eral studies have described “striking similarities”
between pallidotomy and STN DBS at very long-term
follow-up [64] with progress of “axial and akinetic
symptoms”, “cognitive decline” and ”comorbities”
[65–67]. These were mainly attributed to progress
of the disease with appearance of non-dopaminergic
features, while DBS still provided good control for
other symptoms (see below).
STN DBS CREATES A NEW PHENOTYPE
OF PD
Hence, in some patients, long term STN DBS does
result in a dissociation between a preserved good
effect on symptoms of the upper limbs, especially
tremor and rigidity, and a deterioration of axial and
akinetic symptoms [67]. While this is not proof that
STN DBS postpones later stages of the disease, it
suggests that the procedure results in late stage PD
patients who do not shake, and who exhibit less
rigidity and bradykinesia in the hands, but who expe-
rience difficulties with walking, and exhibit freezing
episodes, falls, and cognitive decline [65]. This post-
STN DBS PD phenotype, that is widely recognized
today, was first described by Paul Bejjani et al. in
2008 [68].
FUTURE OF DBS FOR PD
Notwithstanding the current trials using DBS in
many areas of Neurology and Psychiatry, PD remains
the main indication for DBS. Moreover, DBS will
remain the main surgical procedure used in PD
patients, for the foreseeable future [32]. Even after
30 years, the debate continues concerning several
aspects of DBS in PD. For example, is the STN or
GPi the most appropriate brain target? Should surgery
be performed early or late in disease? Should one
use microelectrode recording during surgery or not?
Should DBS surgery be performed with the patient
awake or asleep?
New medical device companies have entered the
DBS market and new technological advances are
being introduced [69]. New DBS leads enabling the
current to be directed in a specific direction perpen-
dicular to the axis of the lead, so called directional
DBS, are being tested [70–72], with the hope of
avoiding side effects by focusing the high frequency
stimulation at the brain target aimed at and away from
structures adjacent to it, and enabling the shaping
the electrical current to “conform” to the anatomy of
the target. Rechargeable stimulators are now avail-
able with a total battery life reported to be between 9
and 25 years, provided they are recharged regularly.
It remains to be seen whether these technological
advances will improve the outcome compared to con-
ventional DBS leads, and conventional stimulation.
Perhaps the most exciting advance for the future
of DBS in PD will be the ability to provide closed-
loop “on demand” stimulation. A delivery of high
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frequency electrical current to the brain target, guided
by the physiological state of the patient, will enable
stimulation to be supplied only when required to
“block” the pathological neuronal firing responsible
for the cardinal symptoms of the patient. Our group
at Queen Square [73], demonstrated that when the
typical 130-Hz stimulation is applied in a fluctuating
PD patient who happens to be in a good ‘on’ state
thanks to medication, the performance on finger tap-
ping scores deteriorates slightly, whereas when that
patient is in an off motor state, STN DBS results in
improved tapping scores. In other words, STN DBS
can negatively interfere with ‘well functioning basal
ganglia circuitry’ when the fluctuating patient is in a
clinical status that does not ‘need’ DBS at that par-
ticular time. The findings of that study suggested that
‘on demand’ DBS, aka “adaptive DBS” (i.e., DBS
triggered by the level of pathological local field poten-
tial Beta activity) would be a more effective way of
delivering stimulation. This theory has subsequently
been tested in a collaboration between our group and
Peter Brown’s group in Oxford, showing that in the
acute phase, during the first few days after surgery
when the electrodes are externalised, an adaptive
stimulation triggered by the Beta activity of the STN
was more efficient than conventional stimulation, and
with a 50% reduction in stimulation time and a corre-
sponding reduction in energy requirements [74]. Our
further experiments with adaptive DBS showed that
it can improve both axial and appendicular symp-
toms and can track the need for stimulation across
drug states [75], as well as reduce side effects such
as dysarthria, compared to conventional continuous
stimulation [76]. It remains to be seen whether these
highly preliminary results, obtained during a short
time frame in experimental settings of adaptive stim-
ulation a few days after surgery, will remain valid
during chronic DBS and in the long term.
CONCLUSIONS
Despite all its associated problems, STN DBS
remains today the main surgical procedure for PD,
mainly, but not solely, due to its effectiveness in
ameliorating PD symptoms, and because it is the
only surgical procedure for PD that allows a radical
decrease in medication.
With over 150 000 patients operated on worldwide,
DBS, especially DBS in the STN, is by far the most
popular surgical procedure for PD. However, it must
be kept in mind that the great majority of PD patients
worldwide who would need surgery have no access
to DBS. This is mainly due to financial reasons, but
also due to the decline of ablative stereotactic surgery
such as pallidotomy even though it has been shown
that unilateral pallidotomy does not harbour more
complications than DBS [77, 78].
DBS for PD is here to stay and it will continue to
fascinate scientists and clinicians alike. A PubMed
search performed on February 3d, 2017, using the
search words “deep brain stimulation” and “Parkin-
son’s disease” yielded 3731 articles. If “deep brain
stimulation” is associated to “subthalamic nucleus”,
the PubMed search provides 2992 papers. This is a
testimony of the scientific importance of DBS and of
the STN, and indeed the 2014 Lasker–DeBakey Clin-
ical Medical Research Award honouring Alim-Louis
Benabid and Mahlon DeLong stated explicitly that it
was delivered to them to “honor two scientists who
developed deep brain stimulation of the subthalamic
nucleus”.
Despite the several decades of activity in DBS
for PD, many controversies are still not resolved,
many developments of the technique are being tri-
alled and many challenges remain. Notwithstanding
these, the fundamental issues of PD remain: How to
tackle the progress of disease, especially the L-dopa-
refractory axial symptoms, affecting speech, gait and
balance, and the cognitive decline? In the meantime,
the improvement brought by DBS to the quality of
life of many patients is beyond doubt, and DBS and
other surgical procedures, can be invaluable in treat-
ing motor and other symptoms due to the nigrostriatal
degeneration, allowing the PD patient to enjoy an
extended period of good quality of life.
For me, DBS, especially DBS for PD, represents
a happy marriage between neurology and neuro-
surgery. In 2003 I baptised the child of that marriage:
“Interventional Neurology” [8].
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